Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Kenneth Carl Anderson, M.D.

Co-Author

Back to Details
This page shows the publications co-authored by Kenneth Anderson and Nikhil Munshi.
Kenneth Anderson
Connection Strength
27.111
Nikhil Munshi
  1. Reply to M. Roschewski et al. J Clin Oncol. 2014 Feb 10; 32(5):478.
    View in: PubMed
    Score: 0.605
  2. Minimal residual disease in multiple myeloma. J Clin Oncol. 2013 Jul 10; 31(20):2523-6.
    View in: PubMed
    Score: 0.580
  3. New strategies in the treatment of multiple myeloma. Clin Cancer Res. 2013 Jul 01; 19(13):3337-44.
    View in: PubMed
    Score: 0.572
  4. Lenalidomide plus dexamethasone is efficacious in patients with relapsed or refractory multiple myeloma. Nat Clin Pract Oncol. 2008 Jul; 5(7):374-5.
    View in: PubMed
    Score: 0.411
  5. Does maintenance therapy with thalidomide benefit patients with multiple myeloma? Nat Clin Pract Oncol. 2007 Jul; 4(7):394-5.
    View in: PubMed
    Score: 0.382
  6. Identification of genes modulated in multiple myeloma using genetically identical twin samples. Blood. 2004 Mar 01; 103(5):1799-806.
    View in: PubMed
    Score: 0.296
  7. Novel biologically based therapies for multiple myeloma. Int J Hematol. 2002 Aug; 76 Suppl 1:340-1.
    View in: PubMed
    Score: 0.274
  8. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.
    View in: PubMed
    Score: 0.247
  9. Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. 2021 Jan 13; 11(1):13.
    View in: PubMed
    Score: 0.246
  10. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020 12 08; 4(23):5988-5999.
    View in: PubMed
    Score: 0.244
  11. YWHAE/14-3-3e expression impacts the protein load, contributing to proteasome inhibitor sensitivity in multiple myeloma. Blood. 2020 07 23; 136(4):468-479.
    View in: PubMed
    Score: 0.238
  12. Genome-Wide Somatic Alterations in Multiple Myeloma Reveal a Superior Outcome Group. J Clin Oncol. 2020 09 20; 38(27):3107-3118.
    View in: PubMed
    Score: 0.238
  13. Correction: BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 Jul; 34(7):1971.
    View in: PubMed
    Score: 0.237
  14. BCMA peptide-engineered nanoparticles enhance induction and function of antigen-specific CD8+ cytotoxic T lymphocytes against multiple myeloma: clinical applications. Leukemia. 2020 01; 34(1):210-223.
    View in: PubMed
    Score: 0.223
  15. The effects of MicroRNA deregulation on pre-RNA processing network in multiple myeloma. Leukemia. 2020 01; 34(1):167-179.
    View in: PubMed
    Score: 0.220
  16. Selective targeting of multiple myeloma by B cell maturation antigen (BCMA)-specific central memory CD8+ cytotoxic T lymphocytes: immunotherapeutic application in vaccination and adoptive immunotherapy. Leukemia. 2019 09; 33(9):2208-2226.
    View in: PubMed
    Score: 0.216
  17. Indatuximab Ravtansine (BT062) Monotherapy in Patients With Relapsed and/or Refractory Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2019 06; 19(6):372-380.
    View in: PubMed
    Score: 0.216
  18. Non-overlapping Control of Transcriptome by Promoter- and Super-Enhancer-Associated Dependencies in Multiple Myeloma. Cell Rep. 2018 12 26; 25(13):3693-3705.e6.
    View in: PubMed
    Score: 0.213
  19. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018 12 06; 132(23):2456-2464.
    View in: PubMed
    Score: 0.210
  20. APRIL signaling via TACI mediates immunosuppression by T regulatory cells in multiple myeloma: therapeutic implications. Leukemia. 2019 02; 33(2):426-438.
    View in: PubMed
    Score: 0.208
  21. Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Leukemia. 2018 12; 32(12):2604-2616.
    View in: PubMed
    Score: 0.205
  22. Long intergenic non-coding RNAs have an independent impact on survival in multiple myeloma. Leukemia. 2018 12; 32(12):2626-2635.
    View in: PubMed
    Score: 0.203
  23. Histone deacetylase (HDAC) inhibitor ACY241 enhances anti-tumor activities of antigen-specific central memory cytotoxic T lymphocytes against multiple myeloma and solid tumors. Leukemia. 2018 09; 32(9):1932-1947.
    View in: PubMed
    Score: 0.201
  24. Ribonucleotide Reductase Catalytic Subunit M1 (RRM1) as a Novel Therapeutic Target in Multiple Myeloma. Clin Cancer Res. 2017 Sep 01; 23(17):5225-5237.
    View in: PubMed
    Score: 0.190
  25. The Role of Minimal Residual Disease Testing in Myeloma Treatment Selection and Drug Development: Current Value and Future Applications. Clin Cancer Res. 2017 Aug 01; 23(15):3980-3993.
    View in: PubMed
    Score: 0.190
  26. Blockade of Deubiquitylating Enzyme USP1 Inhibits DNA Repair and Triggers Apoptosis in Multiple Myeloma Cells. Clin Cancer Res. 2017 Aug 01; 23(15):4280-4289.
    View in: PubMed
    Score: 0.188
  27. Targeting CD38 Suppresses Induction and Function of T Regulatory Cells to Mitigate Immunosuppression in Multiple Myeloma. Clin Cancer Res. 2017 Aug 01; 23(15):4290-4300.
    View in: PubMed
    Score: 0.188
  28. Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma. Blood. 2017 04 20; 129(16):2233-2245.
    View in: PubMed
    Score: 0.186
  29. p53-related protein kinase confers poor prognosis and represents a novel therapeutic target in multiple myeloma. Blood. 2017 03 09; 129(10):1308-1319.
    View in: PubMed
    Score: 0.186
  30. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. JAMA Oncol. 2017 Jan 01; 3(1):28-35.
    View in: PubMed
    Score: 0.186
  31. A novel 3D mesenchymal stem cell model of the multiple myeloma bone marrow niche: biologic and clinical applications. Oncotarget. 2016 Nov 22; 7(47):77326-77341.
    View in: PubMed
    Score: 0.184
  32. Osteoclasts promote immune suppressive microenvironment in multiple myeloma: therapeutic implication. Blood. 2016 09 22; 128(12):1590-603.
    View in: PubMed
    Score: 0.180
  33. Dual NAMPT and BTK Targeting Leads to Synergistic Killing of Waldenström Macroglobulinemia Cells Regardless of MYD88 and CXCR4 Somatic Mutation Status. Clin Cancer Res. 2016 Dec 15; 22(24):6099-6109.
    View in: PubMed
    Score: 0.179
  34. A clinically relevant in vivo zebrafish model of human multiple myeloma to study preclinical therapeutic efficacy. Blood. 2016 07 14; 128(2):249-52.
    View in: PubMed
    Score: 0.178
  35. APRIL and BCMA promote human multiple myeloma growth and immunosuppression in the bone marrow microenvironment. Blood. 2016 06 23; 127(25):3225-36.
    View in: PubMed
    Score: 0.177
  36. The KDM3A-KLF2-IRF4 axis maintains myeloma cell survival. Nat Commun. 2016 Jan 05; 7:10258.
    View in: PubMed
    Score: 0.174
  37. Evidence for a role of the histone deacetylase SIRT6 in DNA damage response of multiple myeloma cells. Blood. 2016 Mar 03; 127(9):1138-50.
    View in: PubMed
    Score: 0.173
  38. Bone Marker-Directed Dosing of Zoledronic Acid for the Prevention of Skeletal Complications in Patients with Multiple Myeloma: Results of the Z-MARK Study. Clin Cancer Res. 2016 Mar 15; 22(6):1378-84.
    View in: PubMed
    Score: 0.173
  39. Combination of a Selective HSP90a/ß Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells. PLoS One. 2015; 10(12):e0143847.
    View in: PubMed
    Score: 0.172
  40. Lenalidomide Enhances Immune Checkpoint Blockade-Induced Immune Response in Multiple Myeloma. Clin Cancer Res. 2015 Oct 15; 21(20):4607-18.
    View in: PubMed
    Score: 0.166
  41. Lenalidomide Polarizes Th1-specific Anti-tumor Immune Response and Expands XBP1 Antigen-Specific Central Memory CD3+CD8+ T cells against Various Solid Tumors. J Leuk (Los Angel). 2015 Jun; 3(2).
    View in: PubMed
    Score: 0.165
  42. Heteroclitic XBP1 peptides evoke tumor-specific memory cytotoxic T lymphocytes against breast cancer, colon cancer, and pancreatic cancer cells. Oncoimmunology. 2014; 3(12):e970914.
    View in: PubMed
    Score: 0.161
  43. Early or delayed transplantation for multiple myeloma in the era of novel therapy: does one size fit all? Hematology Am Soc Hematol Educ Program. 2014 Dec 05; 2014(1):255-61.
    View in: PubMed
    Score: 0.160
  44. Immunotherapy strategies in multiple myeloma. Hematol Oncol Clin North Am. 2014 Oct; 28(5):927-43.
    View in: PubMed
    Score: 0.159
  45. Differential and limited expression of mutant alleles in multiple myeloma. Blood. 2014 Nov 13; 124(20):3110-7.
    View in: PubMed
    Score: 0.159
  46. MYD88-independent growth and survival effects of Sp1 transactivation in Waldenstrom macroglobulinemia. Blood. 2014 Apr 24; 123(17):2673-81.
    View in: PubMed
    Score: 0.153
  47. Novel anti-B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma. Blood. 2014 May 15; 123(20):3128-38.
    View in: PubMed
    Score: 0.153
  48. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014 Mar 06; 123(10):1461-9.
    View in: PubMed
    Score: 0.151
  49. Heterogeneity of genomic evolution and mutational profiles in multiple myeloma. Nat Commun. 2014; 5:2997.
    View in: PubMed
    Score: 0.151
  50. Intracellular NAD? depletion enhances bortezomib-induced anti-myeloma activity. Blood. 2013 Aug 15; 122(7):1243-55.
    View in: PubMed
    Score: 0.146
  51. In vitro and in vivo antitumor activity of a novel alkylating agent, melphalan-flufenamide, against multiple myeloma cells. Clin Cancer Res. 2013 Jun 01; 19(11):3019-31.
    View in: PubMed
    Score: 0.144
  52. Proceedings of the Seventh International Workshop on Waldenström Macroglobulinemia. Clin Lymphoma Myeloma Leuk. 2013 Apr; 13(2):181-3.
    View in: PubMed
    Score: 0.143
  53. Tumor-promoting immune-suppressive myeloid-derived suppressor cells in the multiple myeloma microenvironment in humans. Blood. 2013 Apr 11; 121(15):2975-87.
    View in: PubMed
    Score: 0.141
  54. Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J Immunol. 2013 Feb 01; 190(3):1360-71.
    View in: PubMed
    Score: 0.141
  55. Phase 1 study of pomalidomide MTD, safety, and efficacy in patients with refractory multiple myeloma who have received lenalidomide and bortezomib. Blood. 2013 Mar 14; 121(11):1961-7.
    View in: PubMed
    Score: 0.140
  56. A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell. 2012 Sep 11; 22(3):345-58.
    View in: PubMed
    Score: 0.138
  57. Targeting NAD+ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 2012 Oct 25; 120(17):3519-29.
    View in: PubMed
    Score: 0.138
  58. Canonical and noncanonical Hedgehog pathway in the pathogenesis of multiple myeloma. Blood. 2012 Dec 13; 120(25):5002-13.
    View in: PubMed
    Score: 0.137
  59. Myeloma-specific multiple peptides able to generate cytotoxic T lymphocytes: a potential therapeutic application in multiple myeloma and other plasma cell disorders. Clin Cancer Res. 2012 Sep 01; 18(17):4850-60.
    View in: PubMed
    Score: 0.136
  60. Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma. Blood. 2012 Aug 30; 120(9):1877-87.
    View in: PubMed
    Score: 0.136
  61. A novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma. Br J Haematol. 2012 Jun; 157(6):687-701.
    View in: PubMed
    Score: 0.134
  62. Blockade of XBP1 splicing by inhibition of IRE1a is a promising therapeutic option in multiple myeloma. Blood. 2012 Jun 14; 119(24):5772-81.
    View in: PubMed
    Score: 0.134
  63. The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib. Eur J Haematol. 2012 May; 88(5):446-9.
    View in: PubMed
    Score: 0.133
  64. Latest advances and current challenges in the treatment of multiple myeloma. Nat Rev Clin Oncol. 2012 Feb 21; 9(3):135-43.
    View in: PubMed
    Score: 0.133
  65. The Medical Research Council Myeloma IX trial: the impact on treatment paradigms. Eur J Haematol. 2012 Jan; 88(1):1-7.
    View in: PubMed
    Score: 0.130
  66. Perifosine plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with bortezomib: results of a multicenter phase I/II trial. J Clin Oncol. 2011 Nov 10; 29(32):4243-9.
    View in: PubMed
    Score: 0.129
  67. Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders. Br J Haematol. 2011 Nov; 155(3):349-61.
    View in: PubMed
    Score: 0.129
  68. Significant biological role of sp1 transactivation in multiple myeloma. Clin Cancer Res. 2011 Oct 15; 17(20):6500-9.
    View in: PubMed
    Score: 0.128
  69. Managing multiple myeloma: the emerging role of novel therapies and adapting combination treatment for higher risk settings. Br J Haematol. 2011 Sep; 154(6):755-62.
    View in: PubMed
    Score: 0.127
  70. MGUS and smoldering myeloma: the most prevalent of plasma cell dyscrasias. Oncology (Williston Park). 2011 Jun; 25(7):594, 596.
    View in: PubMed
    Score: 0.126
  71. Consensus recommendations for risk stratification in multiple myeloma: report of the International Myeloma Workshop Consensus Panel 2. Blood. 2011 May 05; 117(18):4696-700.
    View in: PubMed
    Score: 0.123
  72. Immunomodulatory effects of lenalidomide and pomalidomide on interaction of tumor and bone marrow accessory cells in multiple myeloma. Blood. 2010 Oct 28; 116(17):3227-37.
    View in: PubMed
    Score: 0.119
  73. Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid. 2010 Jun 15; 4:215-45.
    View in: PubMed
    Score: 0.118
  74. PI3K/p110{delta} is a novel therapeutic target in multiple myeloma. Blood. 2010 Sep 02; 116(9):1460-8.
    View in: PubMed
    Score: 0.118
  75. The treatment of multiple myeloma patients not eligible for asct. Mediterr J Hematol Infect Dis. 2010 May 03; 2(2):e2010009.
    View in: PubMed
    Score: 0.117
  76. Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma. Blood. 2010 Jul 01; 115(26):5385-92.
    View in: PubMed
    Score: 0.117
  77. Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood. 2010 Aug 05; 116(5):679-86.
    View in: PubMed
    Score: 0.117
  78. A novel Aurora-A kinase inhibitor MLN8237 induces cytotoxicity and cell-cycle arrest in multiple myeloma. Blood. 2010 Jun 24; 115(25):5202-13.
    View in: PubMed
    Score: 0.117
  79. A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells. Blood. 2010 May 06; 115(18):3772-5.
    View in: PubMed
    Score: 0.116
  80. Tailoring treatment for multiple myeloma patients with relapsed and refractory disease. Oncology (Williston Park). 2010 Mar; 24(3 Suppl 2):22-9.
    View in: PubMed
    Score: 0.116
  81. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome. Blood. 2010 Apr 08; 115(14):2827-34.
    View in: PubMed
    Score: 0.114
  82. A high-affinity fully human anti-IL-6 mAb, 1339, for the treatment of multiple myeloma. Clin Cancer Res. 2009 Dec 01; 15(23):7144-52.
    View in: PubMed
    Score: 0.114
  83. Functional interaction of plasmacytoid dendritic cells with multiple myeloma cells: a therapeutic target. Cancer Cell. 2009 Oct 06; 16(4):309-23.
    View in: PubMed
    Score: 0.113
  84. Multicenter, phase I, dose-escalation trial of lenalidomide plus bortezomib for relapsed and relapsed/refractory multiple myeloma. J Clin Oncol. 2009 Dec 01; 27(34):5713-9.
    View in: PubMed
    Score: 0.112
  85. Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance. Blood. 2009 Oct 08; 114(15):3276-84.
    View in: PubMed
    Score: 0.111
  86. The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo. Clin Cancer Res. 2009 Jun 15; 15(12):4028-37.
    View in: PubMed
    Score: 0.110
  87. Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells. Blood. 2009 Jul 30; 114(5):1046-52.
    View in: PubMed
    Score: 0.109
  88. Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma. Blood. 2009 Jul 09; 114(2):371-9.
    View in: PubMed
    Score: 0.109
  89. Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications. Blood. 2009 May 21; 113(21):5228-36.
    View in: PubMed
    Score: 0.108
  90. CS1 promotes multiple myeloma cell adhesion, clonogenic growth, and tumorigenicity via c-maf-mediated interactions with bone marrow stromal cells. Blood. 2009 Apr 30; 113(18):4309-18.
    View in: PubMed
    Score: 0.107
  91. Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res. 2009 Jan 01; 15(1):355-60.
    View in: PubMed
    Score: 0.107
  92. Generation of antitumor invariant natural killer T cell lines in multiple myeloma and promotion of their functions via lenalidomide: a strategy for immunotherapy. Clin Cancer Res. 2008 Nov 01; 14(21):6955-62.
    View in: PubMed
    Score: 0.106
  93. Bortezomib in the front-line treatment of multiple myeloma. Expert Rev Anticancer Ther. 2008 Jul; 8(7):1053-72.
    View in: PubMed
    Score: 0.103
  94. Aplidin, a marine organism-derived compound with potent antimyeloma activity in vitro and in vivo. Cancer Res. 2008 Jul 01; 68(13):5216-25.
    View in: PubMed
    Score: 0.103
  95. Clinical, radiographic, and biochemical characterization of multiple myeloma patients with osteonecrosis of the jaw. Clin Cancer Res. 2008 Apr 15; 14(8):2387-95.
    View in: PubMed
    Score: 0.102
  96. p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications. Br J Haematol. 2008 May; 141(5):598-606.
    View in: PubMed
    Score: 0.101
  97. The role of the bone marrow microenvironment in the pathophysiology of myeloma and its significance in the development of more effective therapies. Hematol Oncol Clin North Am. 2007 Dec; 21(6):1007-34, vii-viii.
    View in: PubMed
    Score: 0.099
  98. Combination of proteasome inhibitors bortezomib and NPI-0052 trigger in vivo synergistic cytotoxicity in multiple myeloma. Blood. 2008 Feb 01; 111(3):1654-64.
    View in: PubMed
    Score: 0.099
  99. Targeting MEK1/2 blocks osteoclast differentiation, function and cytokine secretion in multiple myeloma. Br J Haematol. 2007 Oct; 139(1):55-63.
    View in: PubMed
    Score: 0.098
  100. Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu. Blood. 2008 Aug 15; 112(4):1329-37.
    View in: PubMed
    Score: 0.098
  101. Inhibition of Akt induces significant downregulation of survivin and cytotoxicity in human multiple myeloma cells. Br J Haematol. 2007 Sep; 138(6):783-91.
    View in: PubMed
    Score: 0.097
  102. Alkyl phospholipid perifosine induces myeloid hyperplasia in a murine myeloma model. Exp Hematol. 2007 Jul; 35(7):1038-46.
    View in: PubMed
    Score: 0.096
  103. Multiple myeloma: a prototypic disease model for the characterization and therapeutic targeting of interactions between tumor cells and their local microenvironment. J Cell Biochem. 2007 Jul 01; 101(4):950-68.
    View in: PubMed
    Score: 0.096
  104. Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J Immunol. 2007 Jun 15; 178(12):7730-7.
    View in: PubMed
    Score: 0.096
  105. New drugs for myeloma. Oncologist. 2007 Jun; 12(6):664-89.
    View in: PubMed
    Score: 0.096
  106. Targeting MEK induces myeloma-cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007 Sep 01; 110(5):1656-63.
    View in: PubMed
    Score: 0.095
  107. The treatment of relapsed and refractory multiple myeloma. Hematology Am Soc Hematol Educ Program. 2007; 317-23.
    View in: PubMed
    Score: 0.093
  108. Can thalidomide improve outcome in patients with multiple myeloma? Nat Clin Pract Oncol. 2006 Nov; 3(11):590-1.
    View in: PubMed
    Score: 0.092
  109. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM). Blood. 2007 Feb 01; 109(3):1220-7.
    View in: PubMed
    Score: 0.091
  110. Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615.HCl). Blood. 2007 Feb 15; 109(4):1669-77.
    View in: PubMed
    Score: 0.091
  111. MLN120B, a novel IkappaB kinase beta inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res. 2006 Oct 01; 12(19):5887-94.
    View in: PubMed
    Score: 0.091
  112. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood. 2006 Nov 15; 108(10):3458-64.
    View in: PubMed
    Score: 0.090
  113. Gene expression analysis of B-lymphoma cells resistant and sensitive to bortezomib. Br J Haematol. 2006 Jul; 134(2):145-56.
    View in: PubMed
    Score: 0.090
  114. Role of B-cell-activating factor in adhesion and growth of human multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2006 Jul 01; 66(13):6675-82.
    View in: PubMed
    Score: 0.090
  115. In vivo and in vitro cytotoxicity of R-etodolac with dexamethasone in glucocorticoid-resistant multiple myeloma cells. Br J Haematol. 2006 Jul; 134(1):37-44.
    View in: PubMed
    Score: 0.090
  116. Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications. Blood. 2006 Oct 15; 108(8):2804-10.
    View in: PubMed
    Score: 0.090
  117. The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: interplay of growth factors, their receptors and stromal interactions. Eur J Cancer. 2006 Jul; 42(11):1564-73.
    View in: PubMed
    Score: 0.089
  118. Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells. Blood. 2006 Nov 15; 108(10):3441-9.
    View in: PubMed
    Score: 0.089
  119. FQPD, a novel immunomodulatory drug, has significant in vitro activity in multiple myeloma. Br J Haematol. 2006 Mar; 132(6):698-704.
    View in: PubMed
    Score: 0.088
  120. Perifosine, an oral bioactive novel alkylphospholipid, inhibits Akt and induces in vitro and in vivo cytotoxicity in human multiple myeloma cells. Blood. 2006 May 15; 107(10):4053-62.
    View in: PubMed
    Score: 0.087
  121. Immunomodulatory drug lenalidomide (CC-5013, IMiD3) augments anti-CD40 SGN-40-induced cytotoxicity in human multiple myeloma: clinical implications. Cancer Res. 2005 Dec 15; 65(24):11712-20.
    View in: PubMed
    Score: 0.086
  122. Antimyeloma activity of heat shock protein-90 inhibition. Blood. 2006 Feb 01; 107(3):1092-100.
    View in: PubMed
    Score: 0.085
  123. Dysfunctional T regulatory cells in multiple myeloma. Blood. 2006 Jan 01; 107(1):301-4.
    View in: PubMed
    Score: 0.085
  124. Emerging trends in the clinical use of bortezomib in multiple myeloma. Clin Lymphoma Myeloma. 2005 Sep; 6(2):84-8.
    View in: PubMed
    Score: 0.085
  125. Human anti-CD40 antagonist antibody triggers significant antitumor activity against human multiple myeloma. Cancer Res. 2005 Jul 01; 65(13):5898-906.
    View in: PubMed
    Score: 0.084
  126. Combination therapy with interleukin-6 receptor superantagonist Sant7 and dexamethasone induces antitumor effects in a novel SCID-hu In vivo model of human multiple myeloma. Clin Cancer Res. 2005 Jun 01; 11(11):4251-8.
    View in: PubMed
    Score: 0.083
  127. A SCID-hu in vivo model of human Waldenström macroglobulinemia. Blood. 2005 Aug 15; 106(4):1341-5.
    View in: PubMed
    Score: 0.083
  128. Molecular characterization of PS-341 (bortezomib) resistance: implications for overcoming resistance using lysophosphatidic acid acyltransferase (LPAAT)-beta inhibitors. Oncogene. 2005 Apr 28; 24(19):3121-9.
    View in: PubMed
    Score: 0.083
  129. Seliciclib (CYC202 or R-roscovitine), a small-molecule cyclin-dependent kinase inhibitor, mediates activity via down-regulation of Mcl-1 in multiple myeloma. Blood. 2005 Aug 01; 106(3):1042-7.
    View in: PubMed
    Score: 0.082
  130. A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood. 2005 Jul 15; 106(2):713-6.
    View in: PubMed
    Score: 0.082
  131. SDX-101, the R-enantiomer of etodolac, induces cytotoxicity, overcomes drug resistance, and enhances the activity of dexamethasone in multiple myeloma. Blood. 2005 Jul 15; 106(2):706-12.
    View in: PubMed
    Score: 0.082
  132. Azaspirane (N-N-diethyl-8,8-dipropyl-2-azaspiro [4.5] decane-2-propanamine) inhibits human multiple myeloma cell growth in the bone marrow milieu in vitro and in vivo. Blood. 2005 Jun 01; 105(11):4470-6.
    View in: PubMed
    Score: 0.082
  133. Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma. Cancer Res. 2004 Dec 01; 64(23):8746-53.
    View in: PubMed
    Score: 0.080
  134. p38 MAPK inhibition enhances PS-341 (bortezomib)-induced cytotoxicity against multiple myeloma cells. Oncogene. 2004 Nov 18; 23(54):8766-76.
    View in: PubMed
    Score: 0.080
  135. Focus on multiple myeloma. Cancer Cell. 2004 Nov; 6(5):439-44.
    View in: PubMed
    Score: 0.080
  136. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood. 2004 Dec 15; 104(13):4188-93.
    View in: PubMed
    Score: 0.079
  137. Cytotoxic activity of the maytansinoid immunoconjugate B-B4-DM1 against CD138+ multiple myeloma cells. Blood. 2004 Dec 01; 104(12):3688-96.
    View in: PubMed
    Score: 0.079
  138. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2'-deacetyl-N2'-(3-mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res. 2004 Jul 01; 64(13):4629-36.
    View in: PubMed
    Score: 0.078
  139. Targeting mitochondria to overcome conventional and bortezomib/proteasome inhibitor PS-341 resistance in multiple myeloma (MM) cells. Blood. 2004 Oct 15; 104(8):2458-66.
    View in: PubMed
    Score: 0.078
  140. Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341. Oncogene. 2004 Apr 29; 23(20):3597-602.
    View in: PubMed
    Score: 0.077
  141. Mechanisms by which SGN-40, a humanized anti-CD40 antibody, induces cytotoxicity in human multiple myeloma cells: clinical implications. Cancer Res. 2004 Apr 15; 64(8):2846-52.
    View in: PubMed
    Score: 0.077
  142. Telomerase inhibition and cell growth arrest after telomestatin treatment in multiple myeloma. Clin Cancer Res. 2004 Jan 15; 10(2):770-6.
    View in: PubMed
    Score: 0.076
  143. Transcriptional signature of histone deacetylase inhibition in multiple myeloma: biological and clinical implications. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):540-5.
    View in: PubMed
    Score: 0.075
  144. The bortezomib/proteasome inhibitor PS-341 and triterpenoid CDDO-Im induce synergistic anti-multiple myeloma (MM) activity and overcome bortezomib resistance. Blood. 2004 Apr 15; 103(8):3158-66.
    View in: PubMed
    Score: 0.075
  145. Antitumor activity of lysophosphatidic acid acyltransferase-beta inhibitors, a novel class of agents, in multiple myeloma. Cancer Res. 2003 Dec 01; 63(23):8428-36.
    View in: PubMed
    Score: 0.075
  146. Proteasome inhibitor PS-341 abrogates IL-6 triggered signaling cascades via caspase-dependent downregulation of gp130 in multiple myeloma. Oncogene. 2003 Nov 20; 22(52):8386-93.
    View in: PubMed
    Score: 0.075
  147. Fluorescence imaging of multiple myeloma cells in a clinically relevant SCID/NOD in vivo model: biologic and clinical implications. Cancer Res. 2003 Oct 15; 63(20):6689-96.
    View in: PubMed
    Score: 0.074
  148. Effects of oligonucleotide N3'-->P5' thio-phosphoramidate (GRN163) targeting telomerase RNA in human multiple myeloma cells. Cancer Res. 2003 Oct 01; 63(19):6187-94.
    View in: PubMed
    Score: 0.074
  149. Immunomodulatory drug costimulates T cells via the B7-CD28 pathway. Blood. 2004 Mar 01; 103(5):1787-90.
    View in: PubMed
    Score: 0.074
  150. Superoxide-dependent and -independent mitochondrial signaling during apoptosis in multiple myeloma cells. Oncogene. 2003 Sep 18; 22(40):6296-300.
    View in: PubMed
    Score: 0.074
  151. Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling. Cancer Res. 2003 Sep 15; 63(18):5850-8.
    View in: PubMed
    Score: 0.074
  152. Telomerase inhibition and cell growth arrest by G-quadruplex interactive agent in multiple myeloma. . 2003 Sep; 2(9):825-33.
    View in: PubMed
    Score: 0.074
  153. Insights into the multistep transformation of MGUS to myeloma using microarray expression analysis. Blood. 2003 Dec 15; 102(13):4504-11.
    View in: PubMed
    Score: 0.074
  154. Hsp27 inhibits release of mitochondrial protein Smac in multiple myeloma cells and confers dexamethasone resistance. Blood. 2003 Nov 01; 102(9):3379-86.
    View in: PubMed
    Score: 0.073
  155. NVP-LAQ824 is a potent novel histone deacetylase inhibitor with significant activity against multiple myeloma. Blood. 2003 Oct 01; 102(7):2615-22.
    View in: PubMed
    Score: 0.073
  156. JNK-dependent release of mitochondrial protein, Smac, during apoptosis in multiple myeloma (MM) cells. J Biol Chem. 2003 May 16; 278(20):17593-6.
    View in: PubMed
    Score: 0.072
  157. Molecular sequelae of histone deacetylase inhibition in human malignant B cells. Blood. 2003 May 15; 101(10):4055-62.
    View in: PubMed
    Score: 0.071
  158. Nuclear factor-kappaB p65 mediates tumor necrosis factor alpha-induced nuclear translocation of telomerase reverse transcriptase protein. Cancer Res. 2003 Jan 01; 63(1):18-21.
    View in: PubMed
    Score: 0.070
  159. Identification of genes regulated by 2-methoxyestradiol (2ME2) in multiple myeloma cells using oligonucleotide arrays. Blood. 2003 May 01; 101(9):3606-14.
    View in: PubMed
    Score: 0.070
  160. Essential role of caveolae in interleukin-6- and insulin-like growth factor I-triggered Akt-1-mediated survival of multiple myeloma cells. J Biol Chem. 2003 Feb 21; 278(8):5794-801.
    View in: PubMed
    Score: 0.070
  161. CD40 induces human multiple myeloma cell migration via phosphatidylinositol 3-kinase/AKT/NF-kappa B signaling. Blood. 2003 Apr 01; 101(7):2762-9.
    View in: PubMed
    Score: 0.070
  162. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood. 2003 Mar 15; 101(6):2377-80.
    View in: PubMed
    Score: 0.070
  163. Molecular sequelae of proteasome inhibition in human multiple myeloma cells. Proc Natl Acad Sci U S A. 2002 Oct 29; 99(22):14374-9.
    View in: PubMed
    Score: 0.069
  164. Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341. Blood. 2003 Feb 15; 101(4):1530-4.
    View in: PubMed
    Score: 0.069
  165. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood. 2002 Sep 15; 100(6):2187-94.
    View in: PubMed
    Score: 0.069
  166. Proteasome inhibitor PS-341 inhibits human myeloma cell growth in vivo and prolongs survival in a murine model. Cancer Res. 2002 Sep 01; 62(17):4996-5000.
    View in: PubMed
    Score: 0.069
  167. The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 inhibits growth and migration of multiple myeloma cells in the bone marrow microenvironment. Cancer Res. 2002 Sep 01; 62(17):5019-26.
    View in: PubMed
    Score: 0.069
  168. Telomerase inhibitors as anticancer therapy. Curr Med Chem Anticancer Agents. 2002 Sep; 2(5):567-75.
    View in: PubMed
    Score: 0.069
  169. Activation of NF-kappaB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells: therapeutic implications. Oncogene. 2002 Aug 22; 21(37):5673-83.
    View in: PubMed
    Score: 0.069
  170. Arsenic trioxide inhibits growth of human multiple myeloma cells in the bone marrow microenvironment. . 2002 Aug; 1(10):851-60.
    View in: PubMed
    Score: 0.068
  171. Cytokines modulate telomerase activity in a human multiple myeloma cell line. Cancer Res. 2002 Jul 01; 62(13):3876-82.
    View in: PubMed
    Score: 0.068
  172. beta-lapachone, a novel plant product, overcomes drug resistance in human multiple myeloma cells. Exp Hematol. 2002 Jul; 30(7):711-20.
    View in: PubMed
    Score: 0.068
  173. Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood. 2002 Jun 15; 99(12):4525-30.
    View in: PubMed
    Score: 0.068
  174. Biologic sequelae of nuclear factor-kappaB blockade in multiple myeloma: therapeutic applications. Blood. 2002 Jun 01; 99(11):4079-86.
    View in: PubMed
    Score: 0.068
  175. The biological sequelae of stromal cell-derived factor-1alpha in multiple myeloma. . 2002 May; 1(7):539-44.
    View in: PubMed
    Score: 0.067
  176. NF-kappa B as a therapeutic target in multiple myeloma. J Biol Chem. 2002 May 10; 277(19):16639-47.
    View in: PubMed
    Score: 0.066
  177. Identification of genes regulated by dexamethasone in multiple myeloma cells using oligonucleotide arrays. Oncogene. 2002 Feb 21; 21(9):1346-58.
    View in: PubMed
    Score: 0.066
  178. miR-15a/16-1 deletion in activated B cells promotes plasma cell and mature B-cell neoplasms. Blood. 2021 Apr 08; 137(14):1905-1919.
    View in: PubMed
    Score: 0.062
  179. Treatment of relapsed and refractory multiple myeloma: recommendations from the International Myeloma Working Group. Lancet Oncol. 2021 03; 22(3):e105-e118.
    View in: PubMed
    Score: 0.062
  180. Clinical features associated with COVID-19 outcome in multiple myeloma: first results from the International Myeloma Society data set. Blood. 2020 12 24; 136(26):3033-3040.
    View in: PubMed
    Score: 0.061
  181. Cisplatin-Mediated Upregulation of APE2 Binding to MYH9 Provokes Mitochondrial Fragmentation and Acute Kidney Injury. Cancer Res. 2021 Feb 01; 81(3):713-723.
    View in: PubMed
    Score: 0.061
  182. Clinical Features Associated with COVID-19 Outcome in MM: First Results from International Myeloma Society Dataset. Blood. 2020 Nov 06.
    View in: PubMed
    Score: 0.061
  183. VIS832, a novel CD138-targeting monoclonal antibody, potently induces killing of human multiple myeloma and further synergizes with IMiDs or bortezomib in vitro and in vivo. Blood Cancer J. 2020 11 02; 10(11):110.
    View in: PubMed
    Score: 0.061
  184. Revealing the impact of structural variants in multiple myeloma. Blood Cancer Discov. 2020 Nov; 1(3):258-273.
    View in: PubMed
    Score: 0.060
  185. The immunomodulatory drugs lenalidomide and pomalidomide enhance the potency of AMG 701 in multiple myeloma preclinical models. Blood Adv. 2020 09 08; 4(17):4195-4207.
    View in: PubMed
    Score: 0.060
  186. Preclinical evaluation of CD8+ anti-BCMA mRNA CAR T cells for treatment of multiple myeloma. Leukemia. 2021 03; 35(3):752-763.
    View in: PubMed
    Score: 0.059
  187. Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. Nat Commun. 2020 06 12; 11(1):2996.
    View in: PubMed
    Score: 0.059
  188. Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. J Clin Oncol. 2020 07 20; 38(21):2380-2389.
    View in: PubMed
    Score: 0.059
  189. Timing the initiation of multiple myeloma. Nat Commun. 2020 04 21; 11(1):1917.
    View in: PubMed
    Score: 0.058
  190. Targeting of CD38 by the Tumor Suppressor miR-26a Serves as a Novel Potential Therapeutic Agent in Multiple Myeloma. Cancer Res. 2020 05 15; 80(10):2031-2044.
    View in: PubMed
    Score: 0.058
  191. A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma. Leukemia. 2020 08; 34(8):2150-2162.
    View in: PubMed
    Score: 0.058
  192. Phase I/II trial of the CXCR4 inhibitor plerixafor in combination with bortezomib as a chemosensitization strategy in relapsed/refractory multiple myeloma. Am J Hematol. 2019 11; 94(11):1244-1253.
    View in: PubMed
    Score: 0.056
  193. Genomic landscape and chronological reconstruction of driver events in multiple myeloma. Nat Commun. 2019 08 23; 10(1):3835.
    View in: PubMed
    Score: 0.056
  194. Deciphering the chronology of copy number alterations in Multiple Myeloma. Blood Cancer J. 2019 03 26; 9(4):39.
    View in: PubMed
    Score: 0.054
  195. Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia. Blood Adv. 2018 11 13; 2(21):2937-2946.
    View in: PubMed
    Score: 0.053
  196. Dual PAK4-NAMPT Inhibition Impacts Growth and Survival, and Increases Sensitivity to DNA-Damaging Agents in Waldenström Macroglobulinemia. Clin Cancer Res. 2019 01 01; 25(1):369-377.
    View in: PubMed
    Score: 0.052
  197. The evolving role of transplantation in multiple myeloma: the need for a heterogeneous approach to a heterogeneous disease. Clin Adv Hematol Oncol. 2018 Aug; 16(8):564-574.
    View in: PubMed
    Score: 0.052
  198. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia. 2019 01; 33(1):159-170.
    View in: PubMed
    Score: 0.052
  199. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood. 2018 08 09; 132(6):587-597.
    View in: PubMed
    Score: 0.051
  200. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. Br J Haematol. 2018 07; 182(2):222-230.
    View in: PubMed
    Score: 0.051
  201. Genomic discovery and clonal tracking in multiple myeloma by cell-free DNA sequencing. Leukemia. 2018 08; 32(8):1838-1841.
    View in: PubMed
    Score: 0.051
  202. Prospective Evaluation of Magnetic Resonance Imaging and [18F]Fluorodeoxyglucose Positron Emission Tomography-Computed Tomography at Diagnosis and Before Maintenance Therapy in Symptomatic Patients With Multiple Myeloma Included in the IFM/DFCI 2009 Trial: Results of the IMAJEM Study. J Clin Oncol. 2017 Sep 01; 35(25):2911-2918.
    View in: PubMed
    Score: 0.048
  203. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. N Engl J Med. 2017 04 06; 376(14):1311-1320.
    View in: PubMed
    Score: 0.047
  204. The Mutational Landscape of Circulating Tumor Cells in Multiple Myeloma. Cell Rep. 2017 04 04; 19(1):218-224.
    View in: PubMed
    Score: 0.047
  205. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia. J Immunother Cancer. 2016; 4:90.
    View in: PubMed
    Score: 0.046
  206. A Meta-analysis of Multiple Myeloma Risk Regions in African and European Ancestry Populations Identifies Putatively Functional Loci. Cancer Epidemiol Biomarkers Prev. 2016 12; 25(12):1609-1618.
    View in: PubMed
    Score: 0.045
  207. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 2016 08; 17(8):e328-e346.
    View in: PubMed
    Score: 0.045
  208. Therapeutic Targeting of miR-29b/HDAC4 Epigenetic Loop in Multiple Myeloma. . 2016 06; 15(6):1364-75.
    View in: PubMed
    Score: 0.044
  209. Therapeutic targeting of miR-29b/HDAC4 epigenetic loop in multiple myeloma. Mol Cancer Ther. 2016 Mar 28.
    View in: PubMed
    Score: 0.044
  210. A 13 mer LNA-i-miR-221 Inhibitor Restores Drug Sensitivity in Melphalan-Refractory Multiple Myeloma Cells. Clin Cancer Res. 2016 Mar 01; 22(5):1222-33.
    View in: PubMed
    Score: 0.043
  211. Targeting the miR-221-222/PUMA/BAK/BAX Pathway Abrogates Dexamethasone Resistance in Multiple Myeloma. Cancer Res. 2015 Oct 15; 75(20):4384-4397.
    View in: PubMed
    Score: 0.042
  212. Development of extramedullary myeloma in the era of novel agents: no evidence of increased risk with lenalidomide-bortezomib combinations. Br J Haematol. 2015 Jun; 169(6):843-50.
    View in: PubMed
    Score: 0.042
  213. The Cyclophilin A-CD147 complex promotes the proliferation and homing of multiple myeloma cells. Nat Med. 2015 Jun; 21(6):572-80.
    View in: PubMed
    Score: 0.042
  214. Incidence and clinical features of extramedullary multiple myeloma in patients who underwent stem cell transplantation. Br J Haematol. 2015 Jun; 169(6):851-8.
    View in: PubMed
    Score: 0.041
  215. Pyk2 promotes tumor progression in multiple myeloma. Blood. 2014 Oct 23; 124(17):2675-86.
    View in: PubMed
    Score: 0.040
  216. Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus. Blood. 2014 Aug 28; 124(9):1404-11.
    View in: PubMed
    Score: 0.039
  217. Biomarkers of bone remodeling in multiple myeloma patients to tailor bisphosphonate therapy. Clin Cancer Res. 2014 Aug 01; 20(15):3955-61.
    View in: PubMed
    Score: 0.039
  218. Outcomes in patients with relapsed or refractory multiple myeloma in a phase I study of everolimus in combination with lenalidomide. Br J Haematol. 2014 Aug; 166(3):401-9.
    View in: PubMed
    Score: 0.039
  219. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/ß-catenin/BCL9 pathway. Cancer Res. 2014 Mar 15; 74(6):1801-13.
    View in: PubMed
    Score: 0.038
  220. Phase transitions in human IgG solutions. J Chem Phys. 2013 Sep 28; 139(12):121904.
    View in: PubMed
    Score: 0.037
  221. Identification of human leucocyte antigen (HLA)-A*0201-restricted cytotoxic T lymphocyte epitopes derived from HLA-DOß as a novel target for multiple myeloma. Br J Haematol. 2013 Nov; 163(3):343-51.
    View in: PubMed
    Score: 0.037
  222. Vaccination with dendritic cell/tumor fusions following autologous stem cell transplant induces immunologic and clinical responses in multiple myeloma patients. Clin Cancer Res. 2013 Jul 01; 19(13):3640-8.
    View in: PubMed
    Score: 0.036
  223. Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. Clin Cancer Res. 2013 Apr 15; 19(8):2096-106.
    View in: PubMed
    Score: 0.036
  224. In vivo and in vitro effects of a novel anti-Dkk1 neutralizing antibody in multiple myeloma. Bone. 2013 Apr; 53(2):487-96.
    View in: PubMed
    Score: 0.035
  225. MYD88 L265P in Waldenström macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction. Blood. 2013 Mar 14; 121(11):2051-8.
    View in: PubMed
    Score: 0.035
  226. Endothelial stress products and coagulation markers in patients with multiple myeloma treated with lenalidomide plus dexamethasone: an observational study. Br J Haematol. 2013 Feb; 160(3):351-8.
    View in: PubMed
    Score: 0.035
  227. Response assessment in Waldenström macroglobulinaemia: update from the VIth International Workshop. Br J Haematol. 2013 Jan; 160(2):171-6.
    View in: PubMed
    Score: 0.035
  228. Synthetic miR-34a mimics as a novel therapeutic agent for multiple myeloma: in vitro and in vivo evidence. Clin Cancer Res. 2012 Nov 15; 18(22):6260-70.
    View in: PubMed
    Score: 0.035
  229. Pathological crystallization of human immunoglobulins. Proc Natl Acad Sci U S A. 2012 Aug 14; 109(33):13359-61.
    View in: PubMed
    Score: 0.034
  230. Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Rev Hematol. 2012 Feb; 5(1):51-66; quiz 67-8.
    View in: PubMed
    Score: 0.033
  231. Compartment-Specific Bioluminescence Imaging platform for the high-throughput evaluation of antitumor immune function. Blood. 2012 Apr 12; 119(15):e131-8.
    View in: PubMed
    Score: 0.033
  232. Novel myeloma-associated antigens revealed in the context of syngeneic hematopoietic stem cell transplantation. Blood. 2012 Mar 29; 119(13):3142-50.
    View in: PubMed
    Score: 0.033
  233. Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function. Blood. 2012 Mar 01; 119(9):2074-82.
    View in: PubMed
    Score: 0.033
  234. Management of relapsed and relapsed/refractory multiple myeloma. J Natl Compr Canc Netw. 2011 Oct; 9(10):1209-16.
    View in: PubMed
    Score: 0.032
  235. A phase I safety study of enzastaurin plus bortezomib in the treatment of relapsed or refractory multiple myeloma. Am J Hematol. 2011 Jul; 86(7):573-8.
    View in: PubMed
    Score: 0.032
  236. Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomide. Clin Cancer Res. 2011 May 15; 17(10):3259-71.
    View in: PubMed
    Score: 0.031
  237. Weekly bortezomib in combination with temsirolimus in relapsed or relapsed and refractory multiple myeloma: a multicentre, phase 1/2, open-label, dose-escalation study. Lancet Oncol. 2011 Mar; 12(3):263-72.
    View in: PubMed
    Score: 0.031
  238. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 May 05; 117(18):4691-5.
    View in: PubMed
    Score: 0.031
  239. Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 May 05; 117(18):4701-5.
    View in: PubMed
    Score: 0.031
  240. Molecular and cellular effects of multi-targeted cyclin-dependent kinase inhibition in myeloma: biological and clinical implications. Br J Haematol. 2011 Feb; 152(4):420-32.
    View in: PubMed
    Score: 0.031
  241. Vaccination with dendritic cell/tumor fusion cells results in cellular and humoral antitumor immune responses in patients with multiple myeloma. Blood. 2011 Jan 13; 117(2):393-402.
    View in: PubMed
    Score: 0.030
  242. MicroRNAs 15a/16-1 function as tumor suppressor genes in multiple myeloma. Blood. 2010 Oct 20.
    View in: PubMed
    Score: 0.030
  243. Dual inhibition of akt/mammalian target of rapamycin pathway by nanoparticle albumin-bound-rapamycin and perifosine induces antitumor activity in multiple myeloma. . 2010 Apr; 9(4):963-75.
    View in: PubMed
    Score: 0.029
  244. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anticancer drug activity. Nat Med. 2010 Apr; 16(4):483-9.
    View in: PubMed
    Score: 0.029
  245. Blockade of the MEK/ERK signalling cascade by AS703026, a novel selective MEK1/2 inhibitor, induces pleiotropic anti-myeloma activity in vitro and in vivo. Br J Haematol. 2010 May; 149(4):537-49.
    View in: PubMed
    Score: 0.029
  246. Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A. 2010 Mar 16; 107(11):5124-9.
    View in: PubMed
    Score: 0.029
  247. Conflicts of interest, authorship, and disclosures in industry-related scientific publications. Mayo Clin Proc. 2010 Feb; 85(2):197-9; author reply 201-4.
    View in: PubMed
    Score: 0.029
  248. Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res. 2009 Dec 01; 15(23):7153-60.
    View in: PubMed
    Score: 0.028
  249. Novel therapies in the treatment of multiple myeloma. J Natl Compr Canc Netw. 2009 Oct; 7(9):947-60.
    View in: PubMed
    Score: 0.028
  250. In vitro anti-myeloma activity of the Aurora kinase inhibitor VE-465. Br J Haematol. 2009 Dec; 147(5):672-6.
    View in: PubMed
    Score: 0.028
  251. High-dose zoledronic acid impacts bone remodeling with effects on osteoblastic lineage and bone mechanical properties. Clin Cancer Res. 2009 Sep 15; 15(18):5829-39.
    View in: PubMed
    Score: 0.028
  252. Bortezomib in the management of multiple myeloma. Cancer Manag Res. 2009 Sep 08; 1:107-17.
    View in: PubMed
    Score: 0.028
  253. Prognostic significance of copy-number alterations in multiple myeloma. J Clin Oncol. 2009 Sep 20; 27(27):4585-90.
    View in: PubMed
    Score: 0.028
  254. Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235. Cancer Res. 2009 Jul 15; 69(14):5835-42.
    View in: PubMed
    Score: 0.028
  255. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009 Aug 27; 114(9):1729-35.
    View in: PubMed
    Score: 0.028
  256. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol. 2009 Jul 20; 27(21):3518-25.
    View in: PubMed
    Score: 0.028
  257. Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib. Semin Hematol. 2009 Apr; 46(2):166-75.
    View in: PubMed
    Score: 0.027
  258. Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws? J Oral Maxillofac Surg. 2009 Mar; 67(3):593-601.
    View in: PubMed
    Score: 0.027
  259. CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy. Blood. 2009 Apr 30; 113(18):4341-51.
    View in: PubMed
    Score: 0.027
  260. Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling. Blood. 2009 Feb 12; 113(7):1513-21.
    View in: PubMed
    Score: 0.026
  261. In vivo anti-myeloma activity and modulation of gene expression profile induced by valproic acid, a histone deacetylase inhibitor. Br J Haematol. 2008 Nov; 143(4):520-31.
    View in: PubMed
    Score: 0.026
  262. Telomere maintenance in laser capture microdissection-purified Barrett's adenocarcinoma cells and effect of telomerase inhibition in vivo. Clin Cancer Res. 2008 Aug 01; 14(15):4971-80.
    View in: PubMed
    Score: 0.026
  263. Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin Cancer Res. 2008 Feb 01; 14(3):865-74.
    View in: PubMed
    Score: 0.025
  264. MHC class I chain-related protein A antibodies and shedding are associated with the progression of multiple myeloma. Proc Natl Acad Sci U S A. 2008 Jan 29; 105(4):1285-90.
    View in: PubMed
    Score: 0.025
  265. Neutralizing B-cell activating factor antibody improves survival and inhibits osteoclastogenesis in a severe combined immunodeficient human multiple myeloma model. Clin Cancer Res. 2007 Oct 01; 13(19):5903-9.
    View in: PubMed
    Score: 0.024
  266. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice. Exp Hematol. 2007 Sep; 35(9):1366-75.
    View in: PubMed
    Score: 0.024
  267. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell. 2007 Apr; 11(4):349-60.
    View in: PubMed
    Score: 0.024
  268. High-dose therapy with single autologous transplantation versus chemotherapy for newly diagnosed multiple myeloma: A systematic review and meta-analysis of randomized controlled trials. Biol Blood Marrow Transplant. 2007 Feb; 13(2):183-96.
    View in: PubMed
    Score: 0.023
  269. Graft-versus-tumor response in patients with multiple myeloma is associated with antibody response to BCMA, a plasma-cell membrane receptor. Blood. 2005 May 15; 105(10):3945-50.
    View in: PubMed
    Score: 0.020
  270. A global expression-based analysis of the consequences of the t(4;14) translocation in myeloma. Clin Cancer Res. 2004 Sep 01; 10(17):5692-701.
    View in: PubMed
    Score: 0.020
  271. Complete response to donor lymphocyte infusion in multiple myeloma is associated with antibody responses to highly expressed antigens. Blood. 2004 Jan 15; 103(2):656-63.
    View in: PubMed
    Score: 0.019
  272. Viral antigen-specific CD8+ T-cell responses are impaired in multiple myeloma. Br J Haematol. 2003 Jun; 121(6):842-8.
    View in: PubMed
    Score: 0.018
  273. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol. 2003 Apr; 30(2):121-6.
    View in: PubMed
    Score: 0.018
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
© 2021 President and Fellows of Harvard College
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.